Division of Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Department of Anaesthesia, Harvard Medical School, Boston, Massachusetts, USA.
Infect Immun. 2022 Oct 20;90(10):e0020322. doi: 10.1128/iai.00203-22. Epub 2022 Sep 7.
The Gram-negative pathogen Pseudomonas aeruginosa is a common cause of pneumonia in hospitalized patients. Its increasing antibiotic resistance and widespread occurrence present a pressing need for vaccines. We previously showed that a P. aeruginosa type III secretion system protein, PopB, elicits a strong Th17 response in mice after intranasal (IN) immunization and confers antibody-independent protection against pneumonia in mice. In the current study, we evaluated the immunogenicity and protective efficacy in mice of the combination of PopB (purified with its chaperone protein PcrH) and OprF/I, an outer membrane hybrid fusion protein, compared with immunization with the proteins individually either by the intranasal (IN) or subcutaneous (SC) routes. Our results show that after vaccination, a Th17 recall response from splenocytes was detected only in mice vaccinated with PopB/PcrH, either alone or in combination with OprF/I. Mice immunized with the combination of PopB/PcrH and OprF/I had enhanced protection in an acute lethal P. aeruginosa pneumonia model, regardless of vaccine route, compared with mice vaccinated with either alone or adjuvant control. Immunization generated IgG titers against the vaccine proteins and whole P. aeruginosa cells. Interestingly, none of these antisera had opsonophagocytic killing activity, but antisera from mice immunized with vaccines containing OprF/I, had the ability to block IFN-γ binding to OprF/I, a known virulence mechanism. Hence, vaccines combining PopB/PcrH with OprF/I that elicit functional antibodies lead to a broadly and potently protective vaccine against P. aeruginosa pulmonary infections.
革兰氏阴性病原体铜绿假单胞菌是住院患者肺炎的常见病因。其日益增加的抗生素耐药性和广泛发生迫切需要疫苗。我们之前的研究表明,铜绿假单胞菌 III 型分泌系统蛋白 PopB 在鼻内(IN)免疫后会引发小鼠强烈的 Th17 反应,并赋予小鼠对肺炎的抗体独立保护作用。在目前的研究中,我们评估了 PopB(用其伴侣蛋白 PcrH 纯化)和 OprF/I 的组合在小鼠中的免疫原性和保护效力,OprF/I 是一种外膜混合融合蛋白,与单独通过鼻内(IN)或皮下(SC)途径免疫蛋白质相比。我们的结果表明,接种后,仅在单独或联合使用 OprF/I 接种 PopB/PcrH 的小鼠中,从脾细胞中检测到 Th17 回忆反应。与单独接种或佐剂对照的小鼠相比,联合使用 PopB/PcrH 和 OprF/I 的疫苗接种的小鼠在急性致死性铜绿假单胞菌肺炎模型中具有增强的保护作用,无论疫苗途径如何。免疫产生针对疫苗蛋白和整个铜绿假单胞菌细胞的 IgG 滴度。有趣的是,这些抗血清均没有调理吞噬杀伤活性,但含有 OprF/I 的疫苗免疫小鼠的抗血清具有阻断 IFN-γ 与 OprF/I 结合的能力,这是一种已知的毒力机制。因此,联合使用 PopB/PcrH 和 OprF/I 的疫苗可以引发针对铜绿假单胞菌肺部感染的广泛而有效的保护性疫苗。